We have previously shown that immunization of horses with bovine papillomavirus type 1 (BPV1) L1 virus-like particles (VLPs) is safe and highly immunogenic and that BPV1 and bovine papillomavirus type 2 (BPV2) are closely related serotypes. Here we evaluated the protective potential of a BPV1 L1 VLP vaccine against experimental BPV1 and BPV2 challenge and studied the safety and immunogenicity of a bivalent equine papillomavirus type 2 (EcPV2)/BPV1 L1 VLP vaccine. Fourteen healthy horses were immunized with BPV1 L1 VLPs (100 µg per injection) plus adjuvant on days 0 and 28, while seven remained unvaccinated. On day 42, all 21 horses were challenged intradermally at 10 sites of the neck with 10 7 BPV1 virions per injection. In analogy, 14 horses immunized twice with EcPV2 plus BPV1 L1 VLPs (50 µg each) and seven control animals were challenged with 10 7 BPV2 virions per injection. Immunization with BPV1 L1 VLPs alone induced a robust antibody response (day 42 median titre: 12 800), and BPV1-inoculated skin remained unchanged in 13/14 vaccinated horses. Immunization with the bivalent vaccine was safe, resulted in lower median day 42 antibody titres of 400 for BPV1 and 1600 for EcPV2 and conferred significant yet incomplete cross-protection from BPV2-induced tumour formation, with 11/14 horses developing small, short-lived papules. Control horses developed pseudo-sarcoids at all inoculation sites. The monovalent BPV1 L1 VLP vaccine proved highly effective in protecting horses from BPV1-induced pseudo-sarcoid formation. Incomplete protection from BPV2-induced tumour development conferred by the bivalent vaccine is due to the poorer immune response by immune interference or lower cross-neutralization titres to heterologous BPV2 virions.
INTRODUCTION
Papillomaviruses (PVs) are a family of genetically heterogeneous viruses, which adhere to common biological principles. All PVs consist of an icosahedral capsid composed of 72 L1 protein pentamers termed capsomeres and an illdefined number of L2 protein monomers [1] . The capsid harbours a circular dsDNA genome of up to 8 kbp in length, which contains ORFs for early (E) regulatory and transforming proteins, the late (L) viral capsid proteins L1 and L2 and a non-coding long control region regulating viral replication and transcription [2] . Infection by PVs usually causes benign papillomas or warts. However, persistent infection with oncogenic types is associated with the development of epithelial cancer in a wide range of animal species and in humans, with the best-known example being human cervical cancer [3] .
PVs are usually species specific and are thought to have a strict tropism for keratinocytes and/or fibroblasts [2] . Bovine papillomavirus types 1 and 2 (BPV1, BPV2) are an exception to this rule in that they not only infect bovines but also other ungulate species such as tapirs, giraffes, antelopes or water buffaloes [4] [5] [6] [7] [8] . Importantly, BPV1/2 can also infect equids, e.g. horses, donkeys, zebras or mules [4] . In cattle, BPV1/2 infection commonly leads to the development of transient skin warts [9] . In equids, however, BPV1/2 infection is causally associated with the onset and progression of usually persistent skin tumours termed sarcoids. Although sarcoids do not metastasize, they constitute a considerable health problem. With a prevalence of up to 12 %, sarcoids are the most common tumour type encountered in horses, and upon trauma, small single lesions can develop to larger, fleshy, ulcerated tumours that are difficult to treat and usually recrudesce in a multiple form following unsuccessful therapy [10] .
Squamous cell carcinomas (SCCs) are the most frequent malignant tumour type encountered in equids [11] . SCCs mainly develop at muco-cutaneous junctions with the anogenital region representing a major predilection site. Genital SCCs usually progress from plaques, papillomas or in situ carcinoma. We have identified a novel equine PV termed equine papillomavirus type 2 (EcPV2) and detected viral DNA and transcripts in 100 % of tested genital SCCs and precursor lesions, while only 2.6 % of samples (n=193) collected from healthy equids (n=161) tested positive for EcPV2 DNA [12, 13] . Genital SCCs and precursor lesions are commonly diagnosed in older geldings, possibly because these castrated male horses mostly keep the penis retracted in the prepuce where smegma successively accumulates. Indeed, smegma of SCC-bearing patients was shown to contain high EcPV2 DNA copy numbers and structures that probably correspond to intact virions (unpublished data). Genital SCC therapy usually consists of aggressive surgical intervention, i.e. partial or en bloc resection of the affected organ that may entail post-operative complications and euthanasia of the equid patient [12] . Despite the veterinary importance of sarcoids and genital SCC, there is no vaccine to protect equids from oncogenic PV infections and associated tumour disease.
Research in natural animal PV models has chiefly contributed to a better understanding of PV infection and, importantly, to the establishment and release of prophylactic human papillomavirus (HPV) vaccines. The latter are based on the discovery that recombinant PV L1 proteins spontaneously self-assemble into empty viral capsids termed virus-like particles (VLPs) that proved highly effective in conferring type-specific protection from de novo PV infection [14] .
In order to establish vaccines for prevention of PV-induced sarcoids and SCC, we have generated BPV1 L1 VLPs [15] and conducted a phase I dose escalation trial in horses. Intramuscular administration of 50, 100 and 150 µg VLP in alum was safe and resulted in high titres of BPV1-neutralizing antibodies irrespective of the dosage [16] . In vitro neutralization assays also revealed that genetically highly homologous BPV1 and BPV2 are closely related serotypes, suggesting that anti-BPV1 L1 VLP vaccination would also protect from BPV2 in vivo [17] . Recently, we also generated EcPV2 L1 VLPs and, as a surrogate for infectious wild-type EcPV2 virions, EcPV2 pseudo-virions (PsVs), and established an EcPV2 PsV neutralization assay to assess vaccine efficacy against EcPV2 by immuno-bridging. Serum antibodies raised against EcPV2 L1 VLPs in rabbits and passively transferred to mice protected the latter efficiently and specifically from intravaginal EcPV2 PsV challenge, while pre-immune, BPV1-and HPV16-specific control sera had no protective effect [18] . Finally, we have adapted a reliable BPV1 horse challenge model recapitulating inoculation studies from the 1950s and 1960s [19] [20] [21] .
In the present study, we used this horse model to assess the potential of BPV1 L1 VLPs to protect from experimental BPV1 and BPV2 infection and associated pseudo-sarcoid formation, and also addressed the safety and immunogenicity of a bivalent BPV1/EcPV2 L1 VLP vaccine. Herein we report on our major findings.
RESULTS
Immunization of horses with BPV1 L1 VLPs conferred complete protection from experimental BPV1-associated pseudo-sarcoid formation In a first step, 14 horses were immunized intramuscularly with 100 µg BPV1 L1 VLP plus alum adjuvant on days 0 and 28, while 7 control horses were not immunized (Table 1) . On day 42, immunized and control horses were intradermally inoculated with BPV1 virions at 10 sites of the neck under the tied back mane and then monitored weekly for pseudo-sarcoid development. Serum was collected on day 0 (vaccinated horses only), day 42, after 6 months and after 1 year, and BPV1-neutralizing antibody titres were determined by PsV neutralization assay. As shown in Table 2 , immunization with BPV1 L1 VLPs conferred complete protection from experimental BPV1 infection-associated pseudo-sarcoid development in 13/14 horses, with induced antibody titres ranging between 6400 and 25 600 on the day of inoculation. One year after immunization, antibody titres had dropped to values ranging between <50 (the lowest dilution tested) and 800. One immunized 28-year-old Icelandic horse (no. 125) developed seven papules that reached a maximum diameter of 2 mm and completely regressed within 4 weeks. This horse had a maximum antibody titre of 800 (day 42) that became undetectable (<50) after 6 months and 1 year. In contrast, nonimmunized control horses (n=7) developed pseudo-sarcoids at all inoculation sites (Fig. 1) . The maximum diameter of the lesions ranged between 7 and 16 mm and their persistence ranged between 20 and 36 weeks. In two nonimmunized individuals (nos 105 and 115), inoculation with BPV1 virions induced a type-specific neutralizing immune response with 6 month antibody titres of 200 and 3200 ( Table 2) .
Immunization of horses with bivalent BPV1/EcPV2 L1 VLPs is safe and significantly reduces tumour formation induced by heterologous BPV2 challenge In the second trial, 14 naive horses were immunized on days 0 and 28 with a bivalent vaccine containing 50 µg BPV1 and 50 µg EcPV2 L1 VLPs plus alum adjuvant, while seven individuals remained unvaccinated. On day 42, all 21 horses were inoculated with BPV2 virions and monitored as described above. BPV1-and EcPV2-neutralizing serum antibody titres were determined for days 0 (vaccinated horses only), 42 and 105 (15 weeks). Intramuscular immunizations of horses with the bivalent vaccine were well tolerated and had no adverse local or systemic side effects. EcPV2-neutralizing antibody titres ranged between 200 and 1600 on days 42 and 105 in the group of vaccinated horses and were undetectable (<50) in the control group (Table 3) . BPV1-neutralizing antibody titres ranged between 200 and 400 on day 42. On day 105, titres had increased to 400-102 400 in 8/14 individuals, and remained unchanged in 6/ 14 horses (Table 3) .
Complete vaccination-induced protection from experimental BPV2-associated pseudo-sarcoid development was observed in three individuals (nos 316, 320 and 323) with corresponding BPV1 antibody titres amounting to 400 on day 42 and 400 (no. 316) or 25 600 (nos 320 and 323) on day 105. Seven vaccinated horses developed 2-10 small short-lived papules with maximum diameters of 1-5 mm that persisted for 1-7 weeks (Table 3 ). All control horses developed pseudo-sarcoids at all inoculation sites (10 per horse) with maximum diameters ranging between 7 and 30 mm that persisted for 2-9 weeks. The differences regarding tumour numbers (n), maximum tumour diameters (d) and persistence (p) in vaccinated versus control horses were statistically highly significant at P n =0.0039, P d =0.00015 and P p =0.0016, as determined by Mann-Whitney U test (Fig. 2) .
PBMCs of vaccinated and control horses tested positive for BPV1 but not for BPV2 DNA In the course of the first trial, intact skin and pseudo-sarcoids from control horses as well as PBMCs from control and vaccinated horses were collected during tumour progression and regression and then analysed for the presence of BPV1 E5 DNA by type-specific qualitative PCR and for putative virions by immunocapture PCR (IC/PCR) [22] . Tumour development in control horses was associated with the presence of E5 DNA in 4/7 normal skin samples biopsied from the chest and 10/10 pseudo-sarcoids. The latter also tested mostly positive by IC/PCR. Four of seven PBMC isolates originating from control horses and 4/14 PBMC isolates originating from vaccinated horses also harboured BPV1 E5 DNA (Table 4) . Tumour regression was associated with the presence of E5 DNA in 2/7 skin samples and in 5/5 biopsied pseudo-sarcoids, with 4/5 also scoring positive by IC/PCR. Bi-directional sequencing of all PCR and IC/PCR products revealed a 100 % homology to the BPV1 E5 region of wart-derived wild-type virion used for intradermal horse challenge and corresponding to BPV1 GenBank sequence X02346 (not shown).
During tumour progression, PBMCs and pseudo-sarcoids were likewise collected from BPV1/EcPV2 L1 VLP-immunized and corresponding control horses and screened for the presence of BPV2 E7 DNA. While all PBMCs tested negative, E7 DNA was detected from 5/7 tumours in the control group and from 6/6 tumours tested in the vaccination group (Table 4) .
BPV1 proteins E5 and L1 were expressed in all progressing lesions and, to a lesser extent, in regressing tumours and intact skin taken far away from the lesions Expression of the BPV1 oncoprotein E5 and the major capsid protein L1 was assessed by immunohistochemistry (IHC) from sections of progressing and regressing pseudosarcoids and normal skin (chest) of seven BPV1-challenged control horses. In general, viral E5 and L1 protein expression was confined to dermal fibroblasts as revealed by positive immune signals. Tumour and intact skin epidermis tested negative for viral protein throughout experiments (not shown).
E5 protein was detected in all progressing pseudo-sarcoids, with lesions nos 112 and 114 yielding a weaker signal. All regressing lesions analysed and 3/7 normal skin sections scored positive for E5 protein (Fig. 3 , Table 5 ). IHC staining for BPV1 L1 was recorded for all progressive pseudo-sarcoids and all regressing lesions analysed ( Fig. 3 , Table 5 ).
Histologically, pseudo-sarcoids were almost indistinguishable from naturally occurring sarcoids in that they typically (a) (b) consisted of whirling, fusiform and spindle-shaped fibroblasts ( Fig. 3 ) [23] .
DISCUSSION
Sarcoids and genital SCCs are common tumours in horses and other equids that are difficult if not impossible to treat, especially at late stages of the disease. Both tumour types thus constitute a serious health and welfare problem. In addition, sarcoids and genital SCCs also have an important economic impact in that they can affect the use of the animals as leisure, sport, breeding or working equids, minimize the animals' material value and lead to considerable costs of treatment.
A causal association of PV infection with sarcoid development had already been suspected in the 1950s. Meanwhile, it is accepted that sarcoids develop upon infection by BPV1 and/or BPV2 [10] . Similarly, there is ample evidence that EcPV2 is actively involved in the onset and progression of equine genital SCCs [12, 13, [24] [25] [26] [27] [28] [29] [30] [31] ]. Yet, it is still not clear how BPV1/2 or EcPV2 are transmitted to and between equids. Accordingly, one may argue that this issue should be clarified before attempting to develop VLP-based prophylactic vaccines.
Indeed, BPV1/2 infection of equids was always considered to be abortive, with equids representing a dead-end host and bovines the only source of infectious virions [4] . There were also speculations that infected cells or naked viral DNA may suffice to produce de novo infection in equids as experimentally shown for cottontail rabbit PV [32] . Meanwhile, there are several lines of evidence refuting these theories by showing that intact virions are needed to produce infection and that BPV1 infection of horses can be productive, albeit at a lower level than in the bovine host [19, [33] [34] [35] [36] [37] [38] [39] [40] .
The biology of EcPV2 infection is still largely unknown. However, there is growing evidence that infection is productive, with genital lesions and smegma harbouring EcPV2 virions (unpublished results), and that infection is transmitted between equids, as illustrated by the fact that the few initially healthy horses that tested positive for EcPV2 DNA lived in permanent direct contact with horses bearing genital SCCs [13] .
To generate a prophylactic vaccine for protection of naive equids from de novo BPV1/2 and EcPV2 infections, we have assessed the potential of BPV1 L1 VLPs to protect horses from experimental BPV1 and BPV2 infection, and have also addressed the safety and immunogenicity of a bivalent BPV1 plus EcPV2 L1 VLP vaccine in the horse model. Ab, antibody; S*T, number of tumours per horse (10 inoculation sites); Ø max , maximum tumour diameter in millimetres; P max , tumour persistence in weeks; d, day. *As determined by BPV1 or EcPV2 PsV neutralization assay.
Immunization of horses with the monovalent BPV1 L1 VLP vaccine on days 0 and 28 was safe and induced high titres of BPV1-neutralizing antibodies as shown previously [16] . Importantly, the vaccine conferred complete protection from experimental BPV1-induced tumour formation, while all unvaccinated horses (n=7) developed pseudo-sarcoids at all inoculation sites (10 per horse). Given the massive exposure of horses to virion inoculum compared to that presumably transduced in natural infection, prophylactic vaccination may likely protect equids from natural BPV1 infection and associated sarcoid disease. Since January 2013, we have been monitoring BPV1 L1 VLP-vaccinated mare no. 102 (Tables 1 and 2 ; highlighted in grey), which shares her stall with an older mare affected by multiple sarcoids that had also transmitted disease to her offspring born in 2006. Sequencing of respective intralesional BPV1 E5 genes revealed the same E5 variant in mother and offspring (unpublished data). So far (November 2016), vaccinated mare no. 102 has shown no signs of sarcoid disease. Although mare no. 102 represents a single and hence unrepresentative case, it is noteworthy because disease transmission between donkeys occurred within a few months [36] , while mare no. 102 has remained sarcoid free for the past 3 years (Table 2 ; S. Brandt, personal observation).
The bivalent BPV1/EcPV2 L1 VLP vaccine was well tolerated and conferred significant but incomplete protection from BPV2 challenge. Several factors may have contributed to this result. First, immunization with the bivalent vaccine induced much lower type-specific antibody titres in horses than the monovalent vaccine (for comparison, see Tables 2  and 3 ). In fact, one dose (1 ml) of the monovalent vaccine consisted of 100 µg BPV1 L1 VLP and 250 mg alum in PBS. In contrast, one dose of bivalent vaccine contained only half of the amount, i.e. 50 µg BPV1 L1 VLP in combination with 50 µg EcPV2 L1 VLP and 250 mg alum in PBS. Hence, immune interference by addition of the EcPV2 antigen and halving the dose of BPV1 VLPs may have had a negative impact on the immunogenicity of the BPV1 component of the vaccine as described previously [41] . In order to minimize the duration and consequently the costs of the horse trials, the immunization protocol consisted of two immunizations in a 4 week interval (days 0 and 28). In the BPV1 L1 VLP safety and immunogenicity study conducted in 2007/ 2008, horses were immunized three times, i.e. on days 0 and 28 and after 6 months, conferring long-lasting neutralizing antibody titres [16] . Recent data point to HPV L1 VLP vaccines retaining their long-term efficacy even when administered only two instead of three times. Immunogenicity trials conducted in adolescents have shown that their antibody titres are not inferior to those induced after three VLP doses given over 6 months, provided that two doses are given at least 6 months apart [42] . Hence, the short delay of 4 weeks between the first and the second immunization of the horses may represent another factor explaining the poorer immune response to the bivalent vaccine. At the same time, in the murine system, it was shown that antibody concentrations below the detection limit of the standard PsV assay were still protective [43] . This finding is corroborated by the observation that three horses with d42 BPV1-neutralizing antibody titres of only 400 showed complete protection from BPV2 challenge (Table 3) . In contrast, an old Icelandic horse (no. 125) immunized with the monovalent BPV1 L1 VLP vaccine and d42 antibody titres of 800 showed incomplete protection. This finding further supports that protection is not only determined by type-specific neutralizing antibody titres. Follow-up studies on human vaccines immunized with a quadrivalent vaccine containing L1 VLPs of HPV16, HPV18, HPV6 and HPV11 have shown that anti-HPV18
antibody titres dropped to undetectable levels over time. However, the vaccine still conferred protection from natural HPV18 infection, probably because immunization also induced immune memory [44] . The vaccination-induced isotype and subclass of antibodies may likewise influence protection levels. In monkeys, for example, immunization with the quadrivalent HPV vaccine resulted in high titres of IgA, IgG1, IgG3 and IgG4 antibodies, while a monovalent HPV16 L1 VLP vaccine mainly induced IgG1 antibodies [44] . Finally, it should be mentioned that the polyclonality of induced antibodies entails that only a subset of antibodies recognizes PV type-specific epitopes. We have previously shown that antisera induced by either BPV1 or BPV2 L1 VLP vaccines were able to robustly (cross-) neutralize heterologous as well as homologous types, indicating that BPV1 and BPV2 are closely related serotypes [17] . This close relationship is also illustrated by the observation that intradermal inoculation of horses with BPV2 virions led to an increase of day 105 serum antibody titres in some of the horses (nos 319-323; Table 3 ) as determined by BPV1 PsV (cross-) neutralization assay. Incomplete protection from BPV2 achieved by the bivalent BPV1/EcPV2 L1 VLP vaccine could be due to low titres of cross-neutralization antibodies recognizing BPV2 epitopes. This theory is supported by the fact that the in vitro capacities of anti-BPV1 antibodies to neutralize BPV1 and BPV2 differed by one log [17] .
More work is certainly needed to understand the roles of memory B cells, antibody isotype and subclass, and PV type-specific epitopes in PV-VLP-mediated protection from infection. Currently, we aim at improving the protective efficacy of the bivalent vaccine against BPV2 infection by doubling antigen and adjuvant concentrations.
The potential of the BPV1/EcPV2 L1 vaccine to protect horses from EcPV2 infection and related tumour disease has not been assessed for ethical and technical reasons. Even if EcPV2 virions had been available, we could not rule out the possibility that inoculation of scarified mucosa would lead to invasive carcinomas in the horse. However, we have already shown that passive transfer with rabbit EcPV2 L1 VLP immune sera completely protected mice from experimental vaginal EcPV2 PsV infection [18] . Based on these immune-bridging data and an earlier horse study [16] , the herein evaluated BPV1 L1 VLPs and an improved formula of BPV1/EcPV2 L1 VLPs administered in two doses at least 6 months apart have the potential to effectively protect horses from BPV1/2-and EcPV2-associated tumour disease.
METHODS

Study design
In a previous experiment involving four horses, intradermal inoculation with BPV1 virion at 10 sites of the neck per individual resulted in the development of 10 transient pseudo-sarcoids in three horses and 9 transient pseudosarcoids in one horse. Thus, this BPV1 horse challenge model proved very reliable [19] . However, no data on the efficacy of BPV L1 VLP vaccines in horses exist so far. Therefore, we opted for an unbalanced approach assigning 2Â14 horses to the VLP vaccination and 2Â7 to the control groups to ascertain the statistical validity of the trials. As worst-case scenario, we postulated that the proportion of tumours per 10 inoculation sites would be 0.8. On basis that PV VLP vaccination proved protective in other species, we estimated that vaccination would at least result in 75 % tumour reduction as determined by tumour numbers and sizes. Statistical power analysis (G*Power 3.1, University of Düsseldorf) resulted in an expected power of 0.82 for group sizes of 14 vaccinated and 7 unvaccinated control animals per trial (Table 1) .
Animals
According to statistical considerations, the studies involved a total of 42 horses provided by the Veterinary University of Vienna (n=9) and two private owners (n=33). The horses remained in their usual environment throughout the study and were worked normally as riding or clinic horses except on days they were sedated. All horses underwent a clinical examination with particular emphasis on the presence of sarcoids and genital lesions. Candidates for the BPV2 challenge/EcPV2 phase I trial were also screened for genital EcPV2 infection. To this aim, preputial/clitoral swabs collected from male and female animals were subjected to DNA extraction (Qiagen Blood and Tissue Kit, Qiagen). Obtained DNA was tested for PCR compatibility by standard b-actin PCR and then for EcPV2 DNA as described previously [13] . Only horses that were in general good health, showed no clinical signs of BPV1/2-or EcPV2-associated disease and tested negative for EcPV2-DNA were enrolled. The horses were not randomly assigned to the different study groups but on basis of management criteria. For information on enrolled horses regarding age, gender, coat colour and breed, see Table 1 .
Preparation of VLP-based vaccines and immunization of horses BPV1 and EcPV2 L1 VLPs were generated as described previously. In brief, Sf9 insect cells were infected with BPV1 L1 E5 L1 -c Fig. 3 . E5 and L1 protein expression in a BPV1-induced, progressing pseudo-sarcoid (control horse no. 118). Left: diffuse BPV1 E5 protein staining (IHC Â400; bar, 50 µm). Middle: BPV1 L1 protein is expressed in pseudo-sarcoid fibroblasts; nuclear staining is also seen (bar, 100 µm). Right: negative control (substitution of the primary antibody by PBS; bar, 50 µm). or EcPV2 L1 recombinant baculovirus. Then, self-assembled VLPs were purified by density gradient centrifugation, validated by SDS-PAGE, Coomassie staining and transmission electron microscopy and then stored at À20 C until use [15, 16, 18, [45] [46] [47] .
All vaccine doses (1 ml per dose) were prepared freshly on the day of vaccination, with 250 mg Al(OH) 3 per dose as adjuvant [48] , and 100 µg BPV1 L1 VLP (first trial) or 50 µg BPV1 L1 VLP and 50 µg EcPV2 L1 VLP (second trial) combined in PBS.
Horses assigned to vaccine groups (2Â14) were immunized twice in a 4 week interval (days 0 and 28) by deep intramuscular injection into the left side of the neck using a 20 gauge needle as done previously [16] . Control horses (2Â7) remained unvaccinated (Fig. 1) .
Purification of virions as inocula
Cow warts were obtained by therapeutic excision from affected calves in Austria (BPV1) and Southern Italy (BPV2) (Fig. 1) . Presence of BPV1 or BPV2 DNA was ascertained by PCR from purified cow wart DNA (Qiagen Blood and Tissue Kit, Qiagen) and subsequent amplicon sequence analysis [34] . Then wild-type BPV1 and BPV2 virions were purified according to an established protocol [49] . Concentrations of infectious virion were determined by in vitro focus formation assay [50, 51] . Prior to inoculation, virions were diluted in PBS to final concentrations of 10 7 BPV1 virions per 100 µl and 10 7 BPV2 virions per 50 µl.
Intradermal challenge of horses with virion
In the first trial, 14 vaccinated and 7 control horses were intradermally challenged with BPV1 virion on day 42 after immunization with BPV1 L1 VLPs. Horses were sedated using Detomidine and Butorphanol (V etoquinol). The mane was braided, the neck was clipped and the skin was surgically prepared. Then, inoculation was carried out in a line along the neck by 10 intradermal injections of 100 µl BPV1 virion suspension per injection every ±10 cm using a 23 gauge (g) needle.
To ascertain that intradermal inoculation of horses with BPV2 virion would likewise result in the reliable development of transient pseudo-sarcoids as shown for BPV1 [19] , we conducted a pilot experiment involving two control horses. The latter were intradermally inoculated on the neck with 50 µl BPV2 virion suspension/injection as described above and monitored until lesions had completely resolved. As this experiment proved successful, we then inoculated 14 BPV1/EcPV2 VLP-immunized horses and 5 remaining control horses on day 42 after immunization with BPV2 virion in an analogous manner.
Monitoring
All horses involved were clinically monitored weekly from the day of first immunization (day 0) until pseudo-sarcoids had completely resolved. The vaccination sites were checked for swelling and local inflammation, and the inoculation sites for tumour development and regression. Palpable tumours were measured using a calliper and the largest diameter (width) in millimetres was recorded.
Collection of blood and tissue samples Whole blood (8 ml per horse) for serum preparation was collected immediately before the first immunization (day 0, vaccination groups only) and on the day of inoculation (day 42, all horses). Blood was also taken after 6 and 12 months from horses challenged with BPV1 and after 15 weeks (end of trial) from horses challenged with BPV2 virions, and serum was stored at À20 C until use.
Heparinized blood (48 ml per horse) was taken on the day of inoculation and then at weekly intervals until lesions had completely regressed. Heparinized blood was subjected to PBMC isolation by Ficoll-Paque PLUS (GE Healthcare BioSciences) gradient centrifugation. PBMC aliquots (3 per horse per week) were stored as pellets at À80 C for subsequent DNA isolation.
BPV1 and BPV2-induced pseudo-sarcoids were taken at the time of maximum tumour growth (one lesion per horse). In addition, BPV1-induced lesions were also taken in the course of tumour regression from five control horses. Horses were sedated, and sampling sites were surgically prepared and locally anaesthetized using Lidocaine (V etoquinol). The tumours were excised in toto using a biopsy punch (tumour diameter <5 mm) or by sharp dissection (tumour diameter >5 mm) using a scalpel. Surgical wounds were closed using simple interrupted sutures that were removed 2 weeks after surgery. Tumour aliquots were stored in paraffin at room temperature for IHC or in a native form at À20 C or in immunocapture buffer (BPV1 challenge only) at À20 C [22] .
From horses involved in the BPV1 challenge study (n=21), intact skin samples were likewise taken at the time of first tumour sampling from the cranial pectoral region using a 4 mm biopsy punch and stored in paraffin or in a native form at À20 C.
PsV neutralization assay
Neutralizing serum titres were determined as described previously by BPV1 [16] and EcPV2 PsV neutralization assays [18] . In brief, BPV1 or EcPV2 PsVs containing a plasmid vector coding for secreted placental alkaline phosphatase as a reporter gene were incubated in duplicate in serial dilutions of horse sera and plated onto 293TT cells. After 48 h, alkaline phosphatase secreted into the cell culture medium was detected and measured as mean optical density±SD [52] .
The following controls were included in the tests: a background control (293TT cells in growth medium); a noserum control resulting in maximum alkaline phosphatase secretion set at 100 % (reference; PsV-infected 293TT cells without antiserum); a positive control consisting of PsVs pre-incubated with neutralizing monoclonal anti-BPV1 L1 capsomere antibody 5B6 kindly provided by Richard Roden (John Hopkins University) or polyclonal rabbit anti-EcPV2 L1 antibody established by Schellenbacher et al. [18] ; and a negative control, i.e. PsVs pre-incubated with unspecific anti-HPV16 monoclonal Ab V5 provided by R. Roden. Serum dilutions causing !50 % reduction in secreted placental alkaline phosphatase in comparison to the no-serum control were considered neutralizing.
PCR-and IC/PCR-based analyses DNA extracted from tumours, skin and PBMCs and successfully validated for PCR compatibility by standard equine bactin PCR was subjected to BPV1/2 touchdown PCR as described previously [22, 53] using BPV1/2 E5-or E7-specific primers (5¢-E7-454: GGACGCTGCTACGACTGCTGC; 3¢-E7-976: GATTCCACAGACAGTTCTACACCTGC).
Presence of virion-like structures in BPV1-induced pseudosarcoids was addressed by IC/PCR as described previously [22] . In brief, 0.65 ml MlTI Ultra PCR tubes (Sorenson BioScience) were coated with 50 µl BPV1 L1 capsomerespecific antibody 5B6 diluted 1 : 50 in 0.1 M sodium carbonate buffer, pH 9.6, and incubated at 4 C overnight. Then tubes were washed twice with PBS-Tween [PBS, pH 7.2, and 0.1 % (w/v) Tween 20] and rinsed thrice with PBS. Subsequently, 50 µl tumour extract supernatant or normal skin tissue homogenate (from a healthy individual as negative control) as well as wild-type BPV1 virion diluted 1 : 100 in extraction buffer (positive control) or PBS (no-template control) were applied to pre-coated tubes and incubated at 4 C overnight. After washing thoroughly as described above, E7 PCR was carried out in a total volume of 50 µl/ tube including sarcoid DNA as positive, intact skin DNA as negative and sterile water as no-template controls in the PCR. All PCR and IC/PCR products (16 µl aliquots) were visualized on 1.5 % (w/v) Tris/acetate agarose gels by ethidium bromide staining.
Amplicons of correct size were gel extracted using a QIAEX II Gel Extraction Kit (Qiagen) according to instructions of the manufacturer and subjected to bi-directional sequencing (Eurofins). Subsequent comparative sequence alignments were carried out using BLAST program (http://blast.ncbi.nlm. nih.gov/Blast.cgi).
IHC
Paraffin sections of intact skin and pseudo-sarcoids collected during the tumour progression phase as well as regressing lesions from control horses of trial 1 were analysed for BPV1 E5 and L1 protein expression by IHC as previously described [34, 54] . In brief, sections were de-paraffinized, and endogenous peroxidase activity was blocked by incubation with 0.3 % (w/v) H 2 O 2 in methanol for 20 min. Antigen retrieval was performed by microwave treatment (2Â5 min at 750 W) in citrate buffer, pH 6.0. Slides were washed three times with PBS, blocked with donkey serum (1 : 20 in PBS; Santa Cruz Biotechnology) and then incubated with monoclonal mouse anti-BPV1 L1 Ab 1 H8 (1 : 200; Abcam) or polyclonal sheep anti-BPV1 E5 Ab (1 : 5000 in PBS; a gift from Saveria Campo, University of Glasgow, UK) at room temperature overnight. BPV1 protein-antibody complexes were detected by consecutive incubations with biotinylated goat anti-mouse or donkey anti-sheep Abs (1 : 100 in PBS; Santa Cruz Biotechnology), horseradish-peroxidase-conjugated streptavidin (LSAB Kit, DakoCytomation) and diaminobenzidine (DakoCytomation). Sections were counterstained with Mayer's Haematoxylin (Sigma-Aldrich). Negative control sections were obtained by substitution of the primary Abs by PBS. Sections of a naturally occurring sarcoid served as positive controls. Slides were scored visually, with '++' representing a strong signal, '+' representing a moderate signal and '±' representing a weak signal.
Statistical analysis
The distributions of datasets, i.e. tumour number, size and persistence, resulting from challenge of BPV1/EcPV2-vaccinated versus unvaccinated horses with BPV2 virions were assessed by Shapiro-Wilk normality test [55] . Given that these data were not normally distributed, statistical significance of differences between the vaccination and the control group regarding the number, diameter and persistence of pseudosarcoids was assessed by Mann-Whitney U test [56] .
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